IL301361A - Methods for treating multiple myeloma - Google Patents

Methods for treating multiple myeloma

Info

Publication number
IL301361A
IL301361A IL301361A IL30136123A IL301361A IL 301361 A IL301361 A IL 301361A IL 301361 A IL301361 A IL 301361A IL 30136123 A IL30136123 A IL 30136123A IL 301361 A IL301361 A IL 301361A
Authority
IL
Israel
Prior art keywords
talquetamab
dose
subjects
response
cell
Prior art date
Application number
IL301361A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IL301361A publication Critical patent/IL301361A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Luminescent Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
IL301361A 2020-09-16 2021-09-16 Methods for treating multiple myeloma IL301361A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063079294P 2020-09-16 2020-09-16
US202063116549P 2020-11-20 2020-11-20
US202163187888P 2021-05-12 2021-05-12
PCT/EP2021/075523 WO2022058445A1 (en) 2020-09-16 2021-09-16 Methods for treating multiple myeloma

Publications (1)

Publication Number Publication Date
IL301361A true IL301361A (en) 2023-05-01

Family

ID=77924410

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301361A IL301361A (en) 2020-09-16 2021-09-16 Methods for treating multiple myeloma

Country Status (11)

Country Link
US (1) US20220177584A1 (https=)
EP (1) EP4213945A1 (https=)
JP (1) JP2023542124A (https=)
KR (1) KR20230069959A (https=)
CN (1) CN116322769A (https=)
AU (1) AU2021346129A1 (https=)
BR (1) BR112023004830A2 (https=)
CA (1) CA3194796A1 (https=)
IL (1) IL301361A (https=)
MX (1) MX2023003086A (https=)
WO (1) WO2022058445A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
US20260078195A1 (en) 2022-09-09 2026-03-19 Beijing Mabworks Biotech Co., Ltd Multi-specific antibody binding to bcma, gprc5d and cd3, and use thereof
CN117924485A (zh) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 一种抗gprc5d的多特异性抗体
CN120916780A (zh) 2023-02-28 2025-11-07 詹森生物科技公司 包含双特异性gprc5d/cd3抗体的组合物
AU2024257950A1 (en) * 2023-04-19 2025-12-04 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2024246856A1 (en) 2023-06-01 2024-12-05 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025094085A1 (en) 2023-10-31 2025-05-08 Janssen Biotech, Inc. Combination regimens for treating multiple myeloma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
KR20200041834A (ko) * 2017-06-01 2020-04-22 젠코어 인코포레이티드 Cd123 및 cd3에 결합하는 이중특이성 항체
UA130542C2 (uk) * 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
CA3248329A1 (en) * 2019-07-31 2025-11-29 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d

Also Published As

Publication number Publication date
KR20230069959A (ko) 2023-05-19
US20220177584A1 (en) 2022-06-09
AU2021346129A1 (en) 2023-06-01
BR112023004830A2 (pt) 2023-04-18
CN116322769A (zh) 2023-06-23
JP2023542124A (ja) 2023-10-05
EP4213945A1 (en) 2023-07-26
CA3194796A1 (en) 2022-03-24
MX2023003086A (es) 2023-06-16
WO2022058445A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
US11952426B2 (en) Methods for treating multiple myeloma
US12098210B2 (en) Methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies
US20220177584A1 (en) Methods for treating multiple myeloma
KR20250097946A (ko) 암을 치료하는 방법
KR20250173553A (ko) 다발성 골수종의 치료 방법
US20230295292A1 (en) Methods of treating cancers and enhancing efficacy of gprc5dxcd3 bispecific antibodies
EA050839B1 (ru) Способы лечения множественной миеломы
WO2024094660A1 (en) Cd38 antibodies and uses thereof
TW202608482A (zh) 用於治療多發性骨髓瘤之方法
JP2024508764A (ja) 抗ｖｉｓｔａ抗体及びその使用
CN118414165A (zh) 治疗癌症并增强BCMAxCD3双特异性抗体的功效的方法